undamentalytics Newsletter
Sign in

Artiva Biotherapeutics, Inc. key statistics and ratios

In fiscal 2025, Artiva Biotherapeutics, Inc. had return on equity of -56.5%, debt equal to 0.0% of equity and a current ratio of 8.61. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025
Operating margin−91.6%<−999%—
Net margin−85.8%<−999%—
Free-cash-flow margin−151.3%<−999%—
Return on equity——−56.5%
Return on assets−27.3%−41.5%−49.3%
Asset turnover0.320.00—
Current ratio6.5315.398.61
Debt to equity—0.0%0.0%
R&D as % of revenue150.0%>999%—
Capital spending as % of revenue9.7%255.8%—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: ARTV vs CLNNARTV vs CRVOARTV vs CLDX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Artiva Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Artiva Biotherapeutics, Inc.